Enatuzumab approved in China for the treatment of relapsed or refractory multiple myeloma
March 11, 2025
Source: drugdu
37
On March 10, Pfizer announced that the targeted immunotherapy Iregio® (Enatuzumab) was conditionally approved by the National Medical Products Administration for the treatment of adult patients with relapsed or refractory multiple myeloma who had previously received at least three lines of treatment (including a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody).
https://finance.eastmoney.com/a/202503103341149628.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- a milestone in the rise of domestic production March 12, 2025
- Heavy Ten Year Plan March 12, 2025
- Sino Biopharmaceuticals and Qingpu Biotechnology Reach Exclusive Cooperation Agreement March 12, 2025
- Sino Biopharmaceutical’s innovative drug clinical research results are internationally recognized March 12, 2025
- Yifang Biopharma D-2570 Psoriasis Phase II Clinical Study Results Released March 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
